John James McCormick
Characterisation of cysteamine prodrugs for the treatment of cystinosis and evaluation of liquid fill technology.
McCormick, John James
Cystinosis is a rare, autosomal, recessive disease characterised by raised levels of the amino acid cystine in the cells of most organs in the body which can cause organ damage. The treatment involves the oral administration of the aminothiol, cysteamine (Cystagon(TM)), but this has an offensive taste and smell, can cause vomiting and its metabolites are excreted from the body via breath (halitosis) and sweat, which can cause poor patient compliance. The main research aim was to characterise two cysteamine prodrugs for the treatment of cystinosis and evaluate the suitability of liquid fill technology using prodrugs, or alternative drug models, to determine excipient usage using solubility, stability and capsule shell compatibility data to potentially develop prototype formulations based on liquid fill technology.
MCCORMICK, J.J. 2016. Characterisation of cysteamine prodrugs for the treatment of cystinosis and evaluation of liquid fill technology. Robert Gordon University, MRes thesis.
|Publication Date||May 1, 2016|
|Deposit Date||Feb 1, 2017|
|Publicly Available Date||Feb 1, 2017|
|Keywords||Cystinosis; Formulation; Capsules; Encapsulation; Modified release; Gelucire; Liquid fill technology|
MCCORMICK 2016 Characterisation of cysteamine prodrugs
Publisher Licence URL
Copyright: the author and Robert Gordon University